ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2610

Imaging remission in aortitis associated with giant cell arteritis. Multicenter study with tocilizumab in monotherapy and combined therapy

Adrian Martin-Gutierrez1, Javier Loricera2, Diana Prieto-Peña3, Vicente Aldasoro Cáceres4, Olga Maiz5, Eugenio de Miguel6, Eva Galíndez Agirregoikoa7, Ivan Ferraz Amaro8, Santos Castañeda9 and Ricardo Blanco10, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, 4Hospital Universitario de Navarra, Pamplona, Spain, 5Hospital Universitario de Donosti, Donostia, Spain, 6Hospital Universitario La Paz, Madrid, Spain, 7BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 8Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 9Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 10Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

Meeting: ACR Convergence 2025

Keywords: , , ,

Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: Imaging of Rheumatic Diseases (2609–2614)

Session Type: Abstract Session

Session Time: 3:15PM-3:30PM

Background/Purpose: Aortitis is a frequent and potential severe complication of giant cell arteritis (GCA)(GCA-aortitis). Tocilizumab (TCZ) was approved for the treatment of GCA, but its efficacy in GCA-aortitis has not been specifically studied in randomized clinical trials. GCA-aortitis may be more refractory to TCZ than classic cranial GCA phenotype.Our aim was to assess the effectiveness and safety of TCZ in monotherapy (TCZmono) compared to TCZ combined with conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs)(TCZcombo) in GCA-aortitis in clinical practice. To study associative factors associated with imaging remission.

Methods: Comparative multicenter observational study of GCA-aortitis treated with TCZcombo vs TCZmono. Outcomes, at 12 and 24 months, were: clinical, EULAR, and imaging remission (18F-FDG PET/CT vascular uptake lower than liver uptake), glucocorticoid-sparing effect and safety data. Associative factors associated with imaging remission (multivariable logistic regression) were determined at 24 months.

Results: 196 patients (148 female/48 male) with GCA-aortitis treated with TCZ (136 TCZmono/60 TCZcombo) (Table 1). After 24 months since the initiation of TCZ, imaging remission (50% vs.15.8%; p=0.026) was higher with TCZcombo (Figure). In contrast, there were no differences in EULAR and clinical remission. Prednisone sparing effect was higher in TCZcombo. In addition, a non-statistically lower adverse events rate was observed in TCZcombo (8.7 vs. 13.2 vs. adverse events 100 patients/year; p=0.21). In a multivariable logistic study TCZcombo vs TCZmono increases the imaging remission 5.26-fold (OR 5.26 (95% CI: 1.03-26.85; p=0.046) at 24-month follow-up (Table 2).

Conclusion: In GCA-aortitis, TCZ therapy combined with csDMARDs may be more effective than TCZmono in imaging remission without increasing adverse events.

Supporting image 1Table 1. Main general features of 196 patients with aortitis associated with Giant Cell Arteritis at tocilizumab initiation.

Supporting image 2

Supporting image 3

Disclosures: A. Martin-Gutierrez: None; J. Loricera: AbbVie/Abbott, 5, AstraZeneca, 2, 5, 6, Celgene, 2, 5, 6, Eli Lilly, 5, Janssen, 5, Merck/MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 5, Roche, 2, 5, 6, UCB, 2, 5, 6; D. Prieto-Peña: None; V. Aldasoro Cáceres: None; O. Maiz: None; E. de Miguel: AbbVie, 1, 5, 6, BMS, 6, Eli Lilly, 1, 6, Grunenthal, 6, Janssen, 1, 6, MSD, 6, Novartis, 1, 5, 6, Pfizer, 1, 5, 6, Roche, 5, 6, Sanofi, 6, UCB, 6; E. Galíndez Agirregoikoa: None; I. Ferraz Amaro: None; S. Castañeda: None; R. Blanco: AbbVie/Abbott, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Merck/MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6.

To cite this abstract in AMA style:

Martin-Gutierrez A, Loricera J, Prieto-Peña D, Aldasoro Cáceres V, Maiz O, de Miguel E, Galíndez Agirregoikoa E, Ferraz Amaro I, Castañeda S, Blanco R. Imaging remission in aortitis associated with giant cell arteritis. Multicenter study with tocilizumab in monotherapy and combined therapy [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/imaging-remission-in-aortitis-associated-with-giant-cell-arteritis-multicenter-study-with-tocilizumab-in-monotherapy-and-combined-therapy/. Accessed .

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/imaging-remission-in-aortitis-associated-with-giant-cell-arteritis-multicenter-study-with-tocilizumab-in-monotherapy-and-combined-therapy/